首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice
【2h】

Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice

机译:30 kDa脂肪细胞的蛋白水解裂解产物 补体相关蛋白增加肌肉中的脂肪酸氧化 导致体重减轻

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Adipocyte complement-related protein (30 kDa) (Acrp30), a secreted protein of unknown function, is exclusively expressed in differentiated adipocytes; its mRNA is decreased in obese humans and mice. Here we describe novel pharmacological properties of the protease-generated globular head domain of Acrp30 (gAcrp30). Acute treatment of mice with gAcrp30 significantly decreased the elevated levels of plasma free fatty acids caused either by administration of a high fat test meal or by i.v. injection of Intralipid. This effect of gAcrp30 was caused, at least in part, by an acute increase in fatty acid oxidation by muscle. As a result, daily administration of a very low dose of gAcrp30 to mice consuming a high-fat/sucrose diet caused profound and sustainable weight reduction without affecting food intake. Thus, gAcrp30 is a novel pharmacological compound that controls energy homeostasis and exerts its effect primarily at the peripheral level.
机译:脂肪细胞补体相关蛋白(30 kDa)(Acrp30),一种未知功能的分泌蛋白,仅在分化的脂肪细胞中表达;在肥胖的人类和小鼠中,其mRNA含量降低。在这里,我们描述了蛋白酶产生的Acrp30球状头部结构域(gAcrp30)的新型药理特性。用gAcrp30进行的小鼠急性治疗显着降低了因高脂测试餐或静脉内注射引起的血浆游离脂肪酸水平升高。注射脂质。 gAcrp30的这种作用至少部分是由肌肉中脂肪酸氧化的急剧增加引起的。结果,每天向食用高脂/蔗糖饮食的小鼠服用极低剂量的gAcrp30会导致体重的大幅减少和持续减少,而不会影响食物的摄入量。因此,gAcrp30是一种新型的药理化合物,可控制能量稳态并主要在外周水平发挥其作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号